SynthesisJournal of gastrointestinal cancer2025
An Updated Meta-analysis of Pancreatic Cancer Risk in Patients with Inflammatory Bowel Disease.
Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis meta-analysis aims to systematically evaluate the relationship between inflammatory bowel disease (IBD) and the risk of developing pancreatic cancer (PC).
designSystematic review and meta-analysis.
methodWe searched PubMed (Medline), Web of Science, and Scopus up until September 8, 2024. To evaluate heterogeneity among the studies, we used the chi-square test and the I
resultsWe included a total of 17 studies in our analysis. Overall, patients with IBD showed a higher risk of developing PC, with an OR = 1.69 (95% CI: 1.48-1.93). Specifically, patients with Crohn's disease (CD) had an OR of 1.25 (95% CI: 1.10-1.41), while those with ulcerative colitis (UC) had an OR = 1.27 (95% CI: 1.10-1.45). Furthermore, patients with IBD accompanied by primary sclerosing cholangitis (PSC) displayed a significantly higher risk, with an OR = 3.12 (95% CI: 1.67-5.85). Additionally, there was no evidence of publication bias across all subgroups. Although there was no publication bias, we conducted a trim-and-fill analysis to investigate the small study effect. This analysis revealed that the results were influenced by omitted studies and that the pooled effects would be diluted if the omitted studies were included in the meta-analysis.
conclusionCD and UC are associated with an increased risk of PC, with no significant difference in risk levels between the two conditions. However, having IIBD along with PSC increases the risk of PC threefold.
Indexed as
Identifiers
40603749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.